DOTmed September 18, 2024
Eli Lilly and Company announced a $1 billion expansion of its Limerick, Ireland, manufacturing facility, boosting production of biologic active ingredients, including treatments for early-stage Alzheimer’s disease.
The Indianapolis-based company also completed an $800 million facility in Kinsale, Ireland, which has been producing diabetes and obesity medicines since last year.
The Limerick site, expected to begin operations in 2026, will support Lilly’s Alzheimer’s disease portfolio and other biologic drugs. “These investments will boost the production of some of our medicines, helping millions of people,” said Edgardo Hernandez, Lilly’s executive vice president and head of manufacturing operations.
The additional Limerick investment doubles...
Today's Sponsors
Today's Sponsor